AACR 2026 Poster 7370

Medicines Discovery Catapult Collaboration: End-to-end In Vitro and In Vivo Evaluation of Radiopharmaceuticals in Patient-derived Models

Anita Liu, Bryan Miller, Antonella Di Mambro, Prabhakar Panday, Rosemary Shoop, Esther Kingma, Chiara Da Pieve, Bhushan Rai, Juliana Maynard, Elisabet Fernandez-Potente, Tatiane Takahashi, Bram Herpers, Lucy Harris, Lynne Braidwood, Ludovic Bourre, Benedetta Arno

Discover how targeted radionuclide therapy (TRT) with alpha and beta emitters supports precise cancer treatment while improving the translational relevance of radiopharmaceutical development.

The successful advancement of new radiopharmaceuticals depends on preclinical models that can accurately evaluate target specificity, pharmacokinetics, biodistribution, resistance mechanisms, and therapeutic index. This study shows how combining radiochemistry expertise with clinically relevant patient-derived in vitro and in vivo models creates a stronger framework for characterizing novel radiopharmaceuticals. By integrating these capabilities, researchers can generate more predictive preclinical data, reduce development risk, and better align emerging therapies with clinical needs.

Download this Poster to Discover:

• How robust in vitro and in vivo assays help assess whether novel radiopharmaceuticals are accurately engaging the intended target.
  
  
• Approaches for measuring how radiopharmaceuticals distribute, accumulate, and persist across biologically relevant models.
  
  
• How preclinical assays can reveal treatment limitations, safety margins, and opportunities to optimize efficacy.
  
  
• Combining radiochemistry expertise with clinically relevant models strengthens preclinical characterization and supports clinical decision-making.

Download the Poster Now!